(PharmaNewsWire.Com, September 07, 2019 ) According to the new market research “Indian Heparin Market by Type (Hormonal (Insulin, Teriparatide, Calcitonin), Antibioctic (Colistin, Cycloserine), Low molecular weight heparin (Enaxaparin Sodium, Heparin Sodium), Application (Diabetes, Cancer) - India Forecast to 2022", analyzes and studies the major market drivers, restraints/challenges, and opportunities. The Indian peptide drugs market is expected to reach USD 883.0 Million in 2022 from USD 381.8 Million in 2016 and is expected to register a CAGR of 15.0%. The Indian anticoagulant drugs market is expected to reach USD 170.2 Million in 2022 from USD 127.8 Million in 2016 and is expected to register a CAGR of 4.9%.
The global Indian Heparin market is segmented based on type, Low molecular weight heparin, Low molecular weight heparin, application.
On the basis of type segmentation, The Indian peptide drugs market is classified into hormonal, antifungal, antibiotic, ACE inhibitor and others. The hormonal segment is expected to dominate the Indian peptide drugs market in 2016. Growing incidence and prevalence rate of diabetes in India and rising ageing population are the major driving factors for this segment.
Browse and in-depth TOC on in “Indian Heparin Market "
45 - Tables
15 - Figures
75 - Slides
Based on application, the indian peptide drugs market is segmented into diabetes, infectious disease, cancer, cardiology, osteoporosis, gynecological application, and other applications. In 2016, the diabetes segment is expected to account for the largest share of the Indian peptide drugs market, by application. The growth in the segment can be primarily attributed to increasing incidence and prevalence of diabetes cases in the country.
On the basis of Low molecular weight heparin type, the Indian anticoagulant drugs market is classified into enoxaparin sodium, heparin sodium, fondaparinux, and dalteparin sodium. In 2016, the enoxaparin sodium segment is expected to account for the largest share of the Indian anticoagulant drugs market, by type. Enoxaparin sodium is available as an injectable that helps prevent blood clots in the leg veins of patients who have undergone hip/knee replacements or abdominal surgery. According to Human Pharmaceuticals at Boehringer Ingelheim, in India, approximately 231,132 venous thromboembolism (VTE) procedures occur annually; 53.6% of hospitalized Indian patients are at an increased risk of VTE.
Market Players
Key players operating in the Indian peptide drugs market include Abbott Laboratories (U.S.), Sanofi S.A. (France), Eli Lilly and Company (U.S.), Cipla Limited (India), and Biocon Limited (India), Intas Pharmaceuticals Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), Cadila Pharmaceuticals (India), Lupin Limited (India), Emcure Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Dr. R
Key players operating in the Indian anticoagulant drugs market include Sanofi (France), Emcure Pharmaceutical Pvt. Ltd. (India), Cipla Ltd. (India), Bharat Serum (India), Pfizer Inc. (US), Abbott Laboratories (US), and Lupin Ltd. (India), Dr. Reddy’s Laboratories (India), Intas Pharmaceuticals Ltd. (India), Samarth Life Sciences (India), Claris Lifesciences Limited (India), Gland Pharma Limited (India), Mylan Pharmaceutical (India), Torrent Pharmaceuticals (India), and Micro Labs Ltd. (India). eddy’s Laboratories Limited (India), and Alkem Laboratories Limited (India)
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
